Bone metastatic burden and survival benefit from prostate RT in newly diagnosed metastatic prostate cancer

Exploratory analysis of the STAMPEDE trial found that bone metastasis count and metastasis location based on conventional imaging were associated with overall survival and failure-free survival benefit from prostate radiotherapy in M1 disease.